Latest Articles about GILD

Gilead's Sofosbuvir under European Review - Analyst Blog

Zacks Equity Research — Thu, 23 May 2013 00:27:00 Z

Gilead Sciences Inc. ( GILD ) recently announced that its Marketing Authorisation Application (MAA) for HCV candidate sofosbuvir (formerly GS-7977), submitted to the European Medicines

Pre-Market Most Active for May 22, 2013 : NTAP, PFE, NMR, RDS/A, RDS/B, NOK, SNE, PGTI, IRWD, GILD, VOD, ZNGA

NASDAQ.com News — Wed, 22 May 2013 16:39:56 Z

The NASDAQ 100 Pre-Market Indicator is up 6.53 to 3,032.98. The total Pre-Market volume is currently 4,387,941 shares traded. The following are the most active stocks for the pre-market

Pre-Market Most Active for May 20, 2013 : WCRX, RDS/B, YHOO, ACT, BAC, BP, AU, NBG, GILD, ASML, WBSN, ZNGA

NASDAQ.com News — Mon, 20 May 2013 16:39:56 Z

The NASDAQ 100 Pre-Market Indicator is to 3,026.98. The total Pre-Market volume is currently 9,282,494 shares traded. The following are the most active stocks for the pre-market session :

Pipeline Progress at Gilead - Analyst Blog

Zacks Equity Research — Thu, 16 May 2013 22:29:32 Z

Gilead Sciences, Inc. ( GILD ) recently presented encouraging data on its pipeline candidate idelalisib (formerly GS-1101) from a phase II study (study 101-08: n=64). The study is

Stock Market News for May 13, 2013 - Market News

Zacks Equity Research — Mon, 13 May 2013 18:18:31 Z

Benchmarks finished in the green riding on positive investor sentiment. A few better-than-expected corporate results added to the prevailing optimism. Meanwhile, the Federal Reserve discussed

Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 14, 2013

NASDAQ.com News — Mon, 13 May 2013 15:39:06 Z

Amgen Inc. ( AMGN ) will begin trading ex-dividend on May 14, 2013. A cash dividend payment of $0.47 per share is scheduled to be paid on June 07, 2013. Shareholders who purchased AMGN stock

In Danish Laboratories, Hope Looms Large for a Permanent HIV Cure

Valorie Sands — Wed, 08 May 2013 21:42:00 Z

So far HIV has eluded a permanent cure, yet many newly diagnosed patients can now control the virus with just one pill per day. Most lead relatively normal lives. In developing countries where

Techne Corporation (TECH) Ex-Dividend Date Scheduled for May 08, 2013

NASDAQ.com News — Tue, 07 May 2013 17:00:03 Z

Techne Corporation ( TECH ) will begin trading ex-dividend on May 08, 2013. A cash dividend payment of $0.3 per share is scheduled to be paid on May 24, 2013. Shareholders who purchased TECH

The Markets Now: Dow, S&P Hit New Highs on Employment Report

Christopher Witrak — Fri, 03 May 2013 20:27:00 Z

Stocks have climbed higher after nonfarm employment payrolls increased more than expected in April. The Dow (INDEXDJX:.DJI) reached a new intraday record, crossing above 15,000 for the first

Gilead Misses on Earnings, Sales in 1Q - Analyst Blog

Zacks Equity Research — Fri, 03 May 2013 16:29:01 Z

Gilead Sciences, Inc. 's ( GILD ) first quarter 2013 earnings (excluding special items but including stock option expense) of 45 cents per share missed the Zacks Consensus Estimate of 47

After-Hours Earnings Report for May 2, 2013 : GILD, AIG, CNQ, LNKD, MYL, WFT, FLR, XL, TDC, MHK, MCHP, CPT

NASDAQ.com News — Thu, 02 May 2013 22:00:05 Z

The following companies are expected to report earnings after hours on 05/02/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Gilead Sciences, Inc. ( GILD )

The Markets Now: Stocks Climb Higher After ECB Rate Cut, Jobless Claims Report

Christopher Witrak — Thu, 02 May 2013 21:45:00 Z

Stocks have rebounded after closing lower yesterday. The European Central Bank lowered its refinancing rate to 0.50% from 0.75% to help the continent's banking system. New weekly unemployment

Benzinga Market Primer: Thursday, May 2

Matthew Kanterman — Thu, 02 May 2013 14:53:14 Z

Futures Higher On Central Banks U.S. equity futures rose slightly in early pre-market trade following the FOMC saying that it is prepared to increase or decrease asset purchases depending on the

Double Setback for Gilead - Analyst Blog

Zacks Equity Research — Tue, 30 Apr 2013 23:47:55 Z

Gilead Sciences, Inc ( GILD ) suffered two successive setbacks when the US Food and Drug Administration (FDA) issued complete response letters (CRLs) to the company's HIV candidates,

A Look Ahead: This Week's ETFs to Watch

ETF Professor — Mon, 29 Apr 2013 01:28:16 Z

Last week was another fine one for U.S. stocks as the broader market fought off an array of data points that can only be considered mixed at best to again close higher. With last week's 1.4